Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model

Catheterization and Cardiovascular Interventions

Volumn 65, Issue 2, 2005, Pages 227-232

  Collingwood, Robin ^a   Gibson, Lori ^a   Sedlik, Souad ^b   Virmani, Renu ^c   Carter, Andrew J ^a  

^a BORGESS MEDICAL CENTER   (United States)

^b MEDTRONIC INC   (United States)

^c CVPATH INSTITUTE   (United States)

Author keywords

Cell cycle inhibitors; Restenosis; Stents

Indexed keywords

ABT 578; ACETYLSALICYLIC ACID; CLOPIDOGREL; NIFEDIPINE; PHOSPHORYLCHOLINE; STAINLESS STEEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CATTLE; CELL PROLIFERATION; CORONARY STENT; DOSE RESPONSE; DRUG EFFICACY; DRUG ELUTING STENT; GIANT CELL; NONHUMAN; RESTENOSIS; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY VESSELS; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; GRAFT OCCLUSION, VASCULAR; IMMUNOSUPPRESSIVE AGENTS; PHOSPHORYLCHOLINE; SIROLIMUS; STENTS; SWINE; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 20344378467     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20348     Document Type: Article

References (22)

1. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-195.
2. Suzuki T, Wilenski R, Kopia G, et al. Stent-based sirolimus therapy reduces neointimal formation and in-stent restenosis in a porcine coronary model. Circulation 2001;104:1188-1193.
3. Klugherz BD, Llanos G, Lieuallen W, et al. Stent-based delivery of sirolimus for the prevention of restenosis. Coron Art Dis 2002;13:183-188.
4. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
5. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet 2003;362:1093-1099.
6. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
7. Mollison KW. Tetrazole-containing rapamycin analogs with shortened half-lives. US Patent 6, 329,386; 11 December 2001.
8. Boland JL, Corbeij HA, Van Der Giessen W, et al. Multicenter evaluation of the phosphorylcholine-coated biodivYsio stent in short de novo coronary lesions: the SOPHOS study. Int J Cardiovasc Interv 2000;3:215-225.
9. Galli M, Sommariva L, Prati F, et al. Acute and mid-term results of phosphorylcholine coated stents in primary coronary stenting for acute myocardial infarction. Catheter Cardiovasc Interv 2001;53:182-187.
10. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1991;19:267-274.
11. Kornowski R, Hong MK, Virmani R, Jones R, Vodovotz Y, Leon MB. Granulomatous "foreign body reactions" contribute to exaggerated in-stent restenosis. Coron Art Dis 1999;10:9-14.
12. Carter AJ, Aggarwal M, Kopia G, et al. Long-term effects of sirolimus eluting stents in the porcine coronary model. Cardiovasc Res 2004;63:617-624.
13. Malik N, Gunn J, Shepherd L, Crossman DC, Cumberland DC, Holt CM. Phosphorylcholine-coated stents in porcine coronary arteries: in vivo assessment of biocompatibility. J Invas Cardiol 2001;13:193-201.
14. Hiatt BL, Ikeno F, Yeung AC, Carter AJ. Drug-eluting stents: in quest for the holy grail. Catheter Cardiovasc Interv 2002;57:69-71.
15. Liu X, Huang Y, Hanet C, et al. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv 2003;60:172-178.
16. Whelan DM, van der Giessen WJ, Krabbendam SC, et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000;83:338-345.
17. Lewis AL, Furze JD, Small S, et al. Long-term stability of a coronary stent coating post-implantation. J Biomed Mater Res 2002;63:699-705.
18. Zohlnhofer D, Nuhrenberg TG, Neumann FJ. et al. Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties. Mol Pharmacol 2004;65:880-889.
19. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:1996-1998.
20. Stone GW, Ellis SG, Cox DA, et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
21. Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004;109:1948-1954.
22. Merdeth I. The ENDEAVOR 1 clinical trial: clinical and angiographic outcomes at 4 months - late breaking clinical trials. New Orleans, LA: American College of Cardiology; 2004.